- Home
- MLTX vs CMPS Comparison
MLTX vs CMPS Comparison
Compare MLTX & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MLTX | CMPS |
|---|---|---|
| Founded | 2021 | 2020 |
| Country | Switzerland | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MLTX | CMPS |
|---|---|---|
| Price | $17.80 | $11.26 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 8 |
| Target Price | ★ $27.50 | $25.38 |
| AVG Volume (30 Days) | 901.4K | ★ 4.2M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.95 | $2.25 |
| 52 Week High | $62.75 | $14.76 |
Technical Indicators
Market Signals| Indicator | MLTX | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 48.63 | 50.85 |
| Support Level | $15.89 | $5.37 |
| Resistance Level | $19.24 | $14.76 |
| Average True Range (ATR) | 0.88 | 1.02 |
| MACD | -0.06 | -0.21 |
| Stochastic Oscillator | 40.40 | 24.08 |
Price Performance
Historical ComparisonAbout MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.
About CMPS COMPASS Pathways Plc American Depository Shares
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.